These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 19448055)

  • 21. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases.
    Portaccio E; Amato MP; Siracusa G; Pagliai F; Sorbi S; Guidi S; Bosi A; Saccardi R
    Mult Scler; 2007 Jun; 13(5):676-8. PubMed ID: 17548451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
    Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
    Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M; Paolicelli D; Bellacosa A; Cataldo S
    Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress in the diagnosis and treatment of multiple sclerosis.
    Pender MP
    J Clin Neurosci; 1999 Sep; 6(5):367-372. PubMed ID: 10844772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.
    Gorman MP; Healy BC; Polgar-Turcsanyi M; Chitnis T
    Arch Neurol; 2009 Jan; 66(1):54-9. PubMed ID: 19139299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma chitotriosidase activity in multiple sclerosis.
    Comabella M; Domínguez C; Rio J; Martín-Gallán P; Vilches A; Vilarrasa N; Espejo C; Montalban X
    Clin Immunol; 2009 May; 131(2):216-22. PubMed ID: 19176289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future treatments for relapsing-remitting multiple sclerosis.
    Birnbaum G
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis in Pakistan.
    Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S
    Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.
    Lebrun C; Debouverie M; Jeannin S; Pittion-Vouyovitch S; Bayreuther C; Berthier F
    Mult Scler; 2008 Aug; 14(7):933-9. PubMed ID: 18573824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of multiple sclerosis: case studies.
    Woo DA; Olek MJ; Frohman EM
    Neurol Clin; 2006 May; 24(2):199-214. PubMed ID: 16684629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.